SU14813 is primarily used in research settings as a potent inhibitor of multiple receptor tyrosine kinases (RTKs), including VEGFR2, PDGFRβ, and KIT. Its application is significant in the study of cancer biology, particularly in understanding angiogenesis and tumor growth. By blocking these receptors, SU14813 helps researchers investigate the mechanisms of blood vessel formation in tumors and explore potential therapeutic strategies for cancer treatment. It is also utilized in preclinical studies to evaluate its efficacy in inhibiting tumor progression and metastasis, providing insights into the development of targeted cancer therapies.